In this webinar, Dr. Berman & Grace Bowry explain how to understand a bladder cancer pathology report. They break down key concepts like cancer grade, stage, and tumor types to help bladder cancer patients and caregivers better understand how pathology results guide diagnosis and treatment.
How Bladder Cancer Is Diagnosed
Bladder cancer is often detected when patients experience blood in the urine (hematuria) or pain during urination. A bladder cancer diagnosis typically begins with a cystoscopy, where a camera is inserted through the urethra to examine the bladder. If a tumor is seen, it is removed or biopsied and sent to pathology for analysis. Pathologists then determine whether cancer is present and provide detailed information that shapes next steps in care.
Understanding Cancer Grade
Cancer grade describes how abnormal the tumor cells look under a microscope and helps predict how quickly the cancer may grow or spread.
- Low-grade cancers appear more organized and grow slowly, usually with a lower risk of progression.
- High-grade cancers look more irregular and divide quickly, with a higher risk of recurrence and invasion.
Because grade influences treatment planning, high-grade cancers usually require more frequent cystoscopy follow-ups and may involve therapies such as BCG immunotherapy.
What Cancer Stage Tells You
Cancer stage indicates how deeply the tumor has invaded the bladder wall:
- Non-muscle invasive bladder cancer (NMIBC) includes Ta, Tis (CIS), and T1 tumors that are limited to the bladder lining or supportive tissue.
- Muscle-invasive bladder cancer (MIBC) occurs when tumors penetrate the muscle layer (T2+) and present a higher risk of spreading.
Most bladder cancers are papillary tumors, which grow into the bladder cavity and often recur but may have a good prognosis when low-grade. Carcinoma in situ (CIS) is a flat, high-grade tumor that behaves more aggressively and requires close monitoring.
Challenges and Advances in Pathology
Grading bladder cancer can be complex, and studies show variability between pathologists. To help improve consistency, Dr. Burman’s research is exploring AI-based digital pathology tools that measure cell features like nuclear size and mitotic activity. These new quantitative grading techniques show promise for better predicting recurrence and supporting more personalized treatment planning, though they are not yet available in clinical practice.
What Bladder Cancer Patients Should Know About Their Report
The webinar answered common patient questions, such as the meaning of “muscularis propria present without invasion,” why tissue inflammation may appear after treatments like BCG, and how rare variants like sarcomatoid carcinoma behave. While pathology reports may not always list the stage explicitly, they usually include enough information for clinicians to determine it.
Find Support and Resources for Bladder Cancer Patients and Caregivers
Understanding a pathology report can feel overwhelming, but patients and caregivers do not have to navigate it alone. Bladder Cancer Canada offers educational resources, webinars, guides, and peer support to help individuals better understand their diagnosis and care options. By exploring these tools and staying informed, patients can feel more confident when discussing results with their healthcare team and make empowered decisions throughout their bladder cancer journey.
